Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

  • Save
You might also like
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Ivosidenib FDA approved for relapsed or refractory acute myeloid leukemia
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Cabozantinib FDA approved for treatment of patients with advanced renal cell carcinoma
  • Save
Trastuzumab-biosimilar Ontruzant® FDA approved in several indications
  • Save
©aquir / 123RF Stock Photo FDA approved rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency Adjuvant sunitinib FDA approved for renal cell carcinoma patients at high risk of recurrence following nephrectomy.
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg
  • Save
Nivolumab approved for sorafenib-refractory HCC
  • Save
Olaparib (Lynparza) FDA approved as maintenance for BRCAm ovarian cancer
Ribociclib FDA label updated to include pre- and perimenopausal women
  • Save
©United States Food and Drug Agency CAR-T Axicabtagene ciloleucel FDA approved for relapsed or refractory large B-cell lymphoma
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply